Press Releases | PTC Therapeutics, Inc.

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Year

Apr 20, 2021

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2021 Financial Results

SOUTH PLAINFIELD, N.J. , April 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2021 financial results and provide an update on the company's business and outlook on Tuesday, May 4, 2021

Apr 19, 2021

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , April 19, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2021 it approved non-statutory stock options to purchase an aggregate of 75,085 shares of its common stock and 33,740 restricted stock units ("RSUs"), each representing

Apr 15, 2021

Continued Improvements in Motor Milestones in Infants with Type 1 Spinal Muscular Atrophy After Two Years of Treatment with Evrysdi™

- Evrysdi increased survival and reduced need for permanent ventilation - SOUTH PLAINFIELD, N.J. , April 15, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from Part 2 of the pivotal FIREFISH trial demonstrated that infants with type 1 spinal muscular

Apr 14, 2021

PTC Therapeutics Launches the PTC Pinpoint Direct™ Program for Patient-Initiated Genetic Testing

- Provides easier access to genetic testing for patients with symptoms or diagnosis of cerebral palsy at no charge - SOUTH PLAINFIELD, N.J. , April 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new no-charge, patient-initiated testing program in the United

Apr 07, 2021

PTC Therapeutics Received Gallup's "Don Clifton Strengths-Based Culture" Award

SOUTH PLAINFIELD, N.J. , April 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has been named a winner of the 2021 "Don Clifton Strengths-Based Culture Award" from Gallup. The award recognizes organizations with strong workplace cultures that get the best out

Apr 07, 2021

PTC Therapeutics to Host PTC518 Huntington Disease Deep Dive Webinar

SOUTH PLAINFIELD, N.J. , April 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing the PTC518 Huntington disease (HD) program on Thursday, April 15 at 9 a.m. E.T. The Huntington Disease Deep Dive will provide an overview of PTC's

Apr 01, 2021

PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™

SOUTH PLAINFIELD, N.J. , April 1, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that a $20 million milestone payment was triggered by the first commercial sale of Evrysdi ™ (risdiplam) in the European Union under its License and Collaboration Agreement with Roche.

Mar 30, 2021

PTC Therapeutics Announces the European Approval of Evrysdi™ for the Treatment of Spinal Muscular Atrophy

- First and only at home treatment approved for SMA - - Proven efficacy in adults and children with SMA 2 months and older - SOUTH PLAINFIELD, N.J. , March 30, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the European Commission (EC) has granted marketing

Mar 16, 2021

Results from the Second Year of Evrysdi™ (risdiplam) Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA Patients

- Sustained or improved motor function was observed with 24 months of treatment - - Patients and caregivers reported a greater ability to complete activities of daily livingwith increased independence - SOUTH PLAINFIELD, N.J. , March 16, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT)

Mar 15, 2021

PTC Presents Results from a Real-World Study of Steroid Switching in the Treatment of Patients with Dystrophinopathies

- Desire to slow disease progression and tolerability issues were the primary reasons for switching from prednisone to EMFLAZA® (deflazacort) - - Delayed disease progression and improved benefit-risk reported during the 6-month average follow up after switching to EMFLAZA - SOUTH PLAINFIELD, N.J.

Pagination

First page
Previous page
…
Page 14
Page 15
Current page 16
Page 17
Page 18
…
Next page
Last page